中枢神经系统核素显像的临床应用与进展

陈文新; 何品玉

中枢神经系统核素显像的临床应用与进展

陈文新 , 何品玉

文章导航 > 国际放射医学核医学杂志 > 2008, 32 > 1: (33-36)

引用本文:

Citation:

中枢神经系统核素显像的临床应用与进展

陈文新^,,
何品玉

350001 福州, 福建省立医院核医学科PET-CT中心

通讯作者: 陈文新, wenxinchzt@yahoo.com.cn ;

中图分类号: R817.4

The progress and clinical application of radionuclide neuroimaging

CHEN Wen-xin^,,
HE Pin-yu

PET-CT Center, Department of Nuclear Medicine, Fujian Provicial Hospitial, Fuzhou 350001, China

Corresponding author: CHEN Wen-xin, wenxinchzt@yahoo.com.cn ;

CLC number: R817.4

摘要: 各种特异性脑显像剂不断被推广应用,使放射性核素显像从诊断中枢神经系统疾病和监测疗效发展到观察特异性变化的阶段。简述了帕金森病、癫痫、痴呆、药物成瘾、精神疾病、脑功能活动等核素显像的临床应用及近期研究进展。
- 中枢神经系统 /
- 放射性核素显像 /
- 体层摄影术,发射型计算机
Abstract: Development of site-specific brain radiopharmaceuticals extends the the functional neuroimaging applications in the diagnosis and monitoring treatments of various neurologic and psychiatric disorders. This article highlights recent advances and clinical applications of the functional neuroimaging in Parkinson disease, epilepsy, dementia, substance abuse, psychiatric disorders and brain functional research.
- Central nervous system /
- Radionuclide imaging /
- Tomography,emission-computed
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Rakshi JS, Uema T, Ito K, et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D ¹⁸F-dopa-PET study[J]. Brain, 1999, 122(Pt 9):1637-1650.
[2]	Hwang WJ, Yao WJ, Wey SP, et al. Reproducibility of ^99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease[J]. J Nucl Med, 2004, 45(2):207-213.
[3]	Schreckenberger M, Hagele S, Siessmeier T, et al. The dopamine D2 receptor ligand ¹⁸F-desmethoxflallypride:an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism[J]. Eur J Nucl Med Mol Imaging, 2004, 31(8):1128-1135.
[4]	Pavese N, Evans AH, Tai YF, et al. Clinical correlates of levodopainduced dopamine release in Parkinson disease:a PET study[J]. Neurology, 2006, 67(9):1612-1617.
[5]	左传涛,林祥通,李殿友,等.晚期帕金森病患者脑内¹⁸F-FDG摄取变化及其异常脑内环路机制的探讨[J].中华核医学杂志,2004,24(2):107-109.
[6]	Feigin A, Kaplitt MG, Tang C, et al. Modulation of metabolic brain networks aftcr subthalamic gene therapy for Parkinson's disease[J]. Proc Nad Acad Sci USA, 2007, 104(49):19559-19564.
[7]	Henry TR, Van Heertum RL, et al. Positron emission tomography and single photon emisssion computed tomography in epilepsy care[J]. Semin Nucl Med, 2003, 33(2):88-104.
[8]	Fedi M, Berkovic SF, Marini C, et al. A GABAA receptor mutation causing generalized epilepsy reduces benzodiazepine receptor binding[J]. Neuroing, 2006, 32(3):995-1000.
[9]	Bouvard S, Costes N, Bonnefoi F, et al. Seizure-related short-term plasticity of benzodiazeplne receptors in partial epilepsy:a ¹¹C-flumazenil-PET study[J]. Brain, 2005, 128(Pt6):1330-1343.
[10]	Umeoka S, Matsuda K, Baba K, et al. Usefulness of ¹²³I-iomazenil single-photon emission computed tomography in discriminating between mesial and lateral temporal lobe epilepsy in patients in whom magnetic resonance imaging demonstrates normal findings[J]. Neurosurg, 2007, 107(2):352-363.
[11]	Goerres GW, Revesz T, Duncan J, et al. Imaging cerebral vasculitis in refractory epilepsy using ¹¹C (R)-PK11195 positron emission tomography[J]. Am J Roentgenol, 2001, 176(4):1016-1018.
[12]	Drayer B, Jaszczak R, Coleman E, et al. Muscarinic cholinergic receptor binding:In vivo depiction using single photon emission computed tomography and radioiodinated quinuclidinyl benzilate[J]. J Comput Assist Tomogr, 1982, 6(3):536-543.
[13]	Herholz K, Weisenbach S, Zündorf G, et al. In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease[J]. Neuroimage, 2004, 21(1):136-143.
[14]	Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of alterations in aeetyleholinesterase in Alzheimer's disease. Neurosci Lett, 2005, 380(1-2):127-132.
[15]	Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B[J]. Ann Neurol, 2004, 55(3):306-319.
[16]	Mintun MA, Larossa GN, Sheline YI,et al. ¹¹C-PIB in a nondemented population:potential antecedent marker of Alzheimer disease[J]. Neurology, 2006, 67(3):446-452.
[17]	Yoshita M, Taki J, Yokoyama K, et al. Value of ¹²³I-MIBG radioactivity in the differential diagnosis of DLB from AD[J]. Neurology, 2006, 66(12):1850-1854.
[18]	Hanyu H, Shimizu S, Hirao K, et al. Comparative value of brain perfusion SPECT and ¹²³I-MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease[J]. Eur J Nucl Med Mol Imaging, 2006, 33(3):248-253.
[19]	Volkow ND, Chang L, Wang GJ, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence[J]. J Neurosci, 2001, (23):9414-9418.
[20]	Volkow ND, Fowler JS, Gatley SJ, et al. PET evaluation of the dopamine system of the human brain[J]. J Nucl Med, 1996, 37(7):1242-1256.
[21]	Chon Y H, Huang WS, Su TP, et al. Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence:A SPECT study[J]. Eur Neuropsychopharmacol, 2007, 17(1):46-52.
[22]	Potkin SG, Alva G, Fleming K, et al. A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography[J]. Am J Psychiatry, 2002, 159(2):227-237.
[23]	Parsey RV, Hastings RS, Oquendo MA. et al. Lower semtonin transporter binding potential in the human brain during major depressive episodes[J]. Am J Psychiatry, 2006, 163(1):52-58.
[24]	Yasuno F, Suhara T, Okubo Y, et al. Abnormal effective connectivity of dopamine D2 receptor binding in schizophrenia[J]. Psychiatry Res, 2005, 138(3):197-207.
[25]	Feng CM, Narayana S, Lancaster JL, et al. CBF changes during brain activation:fMRI vs. PET. Neuroimage, 2004, 22(1):443-446.
[26]	Laureys S, Owen AM, Schiff ND. Brain function in coma, vegetative state, and related disorders. Lancet Neurol, 2004, 3(9):537-546.
[27]	张向宇,高硕,赵建国,等.不同穴位组合对脑梗死患者脑葡萄糖代谢的影响——PET研究[J].中国针灸,2007,27(1):26-30.
[28]	Palmedo H, Urbach H, Bender H, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma:correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging, 2006, 33(2):164-168.

[1]	骆建华 , 曾兴炳 , 常力方 . 中枢神经系统的放射损伤及其处理. 国际放射医学核医学杂志, 1999, 23(2): 79-82.
[2]	邱春 , 管一晖 . 5-羟色胺受体显像剂在神经系统疾病及脑功能研究中的应用. 国际放射医学核医学杂志, 2011, 35(2): 73-80, 127. doi: 10.3760/cma.j.issn.1673-4114.2011.02.003
[3]	龚守良 . 电离辐射对中枢神经系统的作用. 国际放射医学核医学杂志, 2001, 25(5): 221-224.
[4]	王冰 , 周湘艳 , 崔凤梅 . 氚β粒子照射对发育中的中枢神经系统的影响及机制研究. 国际放射医学核医学杂志, 2023, 47(10): 615-625. doi: 10.3760/cma.j.cn121381-202309012-00367
[5]	张燕 , 陈肖华 . 中枢神经系统辐射损伤的细胞与分子机制研究进展. 国际放射医学核医学杂志, 2004, 28(1): 41-44.
[6]	张玮 , 王利利 , 涂彧 . 中枢神经系统电离辐射效应的细胞和分子机制研究进展. 国际放射医学核医学杂志, 2008, 32(3): 179-182.
[7]	胡旋 , 李锐 . 放射性微球技术测定脊髓血流量的实验观察. 国际放射医学核医学杂志, 2007, 31(4): 215-216.
[8]	吕荣彬 , 韩梅 , 刘兴党 . 人脑功能显像研究药物成瘾的新进展. 国际放射医学核医学杂志, 2009, 33(4): 210-214. doi: 10.3760/cma.j.issn.1673-4114.2009.04.006
[9]	李林法 . ¹⁸F-氟代脱氧葡萄糖正电子发射体层显像在感染与炎症病变中的应用. 国际放射医学核医学杂志, 2006, 30(1): 26-29.
[10]	李祖贵 . 轻度认知障碍的功能性神经影像学研究进展. 国际放射医学核医学杂志, 2006, 30(2): 76-79.
[11]	邢宇 , 赵新明 . 放射性核素标记HER2亲和体分子探针精准诊疗的研究进展. 国际放射医学核医学杂志, 2016, 40(2): 139-144. doi: 10.3760/cma.j.issn.1673-4114.2016.02.011